Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Stereotactic ablative radiotherapy improves median survival for elderly Dutch NSCLC patients

New developments such as stereotactic ablative radiotherapy and improvements in surgical care in early-stage lung cancer have led to large survival gains for elderly Dutch patients, according to a population-based study presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

6 Jul 2011

Answering cancer patients' questions individually will help them master the situation

Small details in the information and how the information is communicated are important to cancer patients. The patients experience lack of knowledge about their illness and the radiotherapy. The situation is cause for strong emotions, but with customized information it can be changed to an ability to master the situation. This is demonstrated in radiation therapist Mariette Abrahamsson's master's thesis at the Nordic School of Public Health (NHV).

4 Jul 2011

Molecular radiotherapy offers hope for children with neuroblastoma

A new treatment option may soon be available for children with neuroblastoma according to research published in the July issue of The Journal of Nuclear Medicine.

30 Jun 2011

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.

27 Jun 2011

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Arno Therapeutics, Inc. announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with Avastin and will continue toward completion.

23 Jun 2011

Varian receives 2011 R&D 100 Award for TrueBeam system for image-guided radiotherapy and radiosurgery

Varian Medical Systems today announced that the company's TrueBeam system for image-guided radiotherapy and radiosurgery has received a 2011 R&D 100 Award from R&D Magazine. This annual award salutes the 100 most technologically significant products of the prior year, spanning many categories, from biomedical products to consumer items.

23 Jun 2011

Proton beam radiotherapy appears to control breast cancer with minimal side-effects

A treatment that has virtually no side effects has been found to be an effective weapon for fighting early-stage breast cancer, according to results of a clinical trial conducted at Loma Linda University Medical Center.

23 Jun 2011

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.

22 Jun 2011

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech, a member of the Roche Group, announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011

New weapon in the fight against cancer

A cancer diagnosis is not necessarily a death sentence. There are now quite a number of possibilities to treat cancer. In addition to radiotherapy and chemotherapy, so-called radionuclide treatment has also become an important component in the fight against the mutated cells. It involves injecting radioactive elements, so-called nuclides, into the patient's circulatory system.

17 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

Varian receives marketing approval for TrueBeam image-guided radiotherapy and radiosurgery system in Japan

Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced today it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan.

15 Jun 2011

Childhood cancer survivors at increased risk of new cancers in middle age

CANCER RESEARCH UK scientists have found that survivors of childhood cancers are four times more likely than the general population to develop a new cancer. The results are published online today in JAMA.

15 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Akademiska Hus, NCC to build Skandion Clinic for advanced radiotherapy in Uppsala

NCC Construction Sweden will construct the Nordic region's first clinic for advanced radiotherapy using proton treatment in Uppsala, Sweden. The customer is Akademiska Hus and the construction contract is valued at SEK 470 million. The project is being conducted as a partnership between NCC and Akademiska Hus.

9 Jun 2011

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRIC has been completed.

9 Jun 2011

Brainlab enters into definitive agreement to acquire Voyant Health

Brainlab announced today that it has entered into a definitive agreement to acquire Voyant Health.

7 Jun 2011

Radiotherapy News and Research

Further Reading

Stereotactic ablative radiotherapy improves median survival for elderly Dutch NSCLC patients

Answering cancer patients' questions individually will help them master the situation

Molecular radiotherapy offers hope for children with neuroblastoma

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Varian receives 2011 R&D 100 Award for TrueBeam system for image-guided radiotherapy and radiosurgery

Proton beam radiotherapy appears to control breast cancer with minimal side-effects

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

New weapon in the fight against cancer

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Varian receives marketing approval for TrueBeam image-guided radiotherapy and radiosurgery system in Japan

Childhood cancer survivors at increased risk of new cancers in middle age

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Akademiska Hus, NCC to build Skandion Clinic for advanced radiotherapy in Uppsala

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Brainlab enters into definitive agreement to acquire Voyant Health

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News